• VivoSim attended the European Society of Toxicology In Vitro annual conference (ESTIV 2026) in Maastricht, running June 29 to July 2.
• It presented data showing its NAMkind Liver model reached 91% predictive accuracy with 90% sensitivity, outperforming animal tests at 50%-65% sensitivity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content used to generate this news brief on June 29, 2026, and is solely responsible for the information contained therein.